FEBRUARY 18, 2012

Browse Categories

ASCO 2009 - A Multicenter Phase II Study of Cisplatin, Gemcitabine, and Bevacizumab as First-Line Chemotherapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU-0475 - Session Highlights

Wed, 03 June 2009
E-mail Print

ORLANDO, FL, USA (UroToday.com) - This study investigated the addition of bevacizumab to the standard regimen of cisplatin/gemcitabine as first-line therapy for patients with metastatic urothelial carcinoma (UC).




Your session will expire in 8 hours requiring you to log in each day to view content.
Share |